 Modular assembly of antibody genes, antibodies prepared thereby and use |
| What is claimed is: 1. A polynucleotide molecule encoding an immunoglobulin fragment, said ... |
|
| Cytoplasmic bacteriophage display system |
| The present invention relates, in one aspect, to a display vector comprising DNA encoding a portion ... |
|
| Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions |
| AND ADVANTAGES According to the present invention, a method of diagnosing and determining the ... |
|
| Polyvalent display libraries |
| I. General The present invention is directed to inter alia two related but self-sufficient ... |
|
| Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
| OF THE INVENTION A. Definitions Amino Acid Residue: An amino acid formed upon chemical digestion (... |
|
| Pharmaceutical and diagnostic business systems and methods |
| Improved business methods, devices, and systems for utilizing genetic information are provided. A... |
|
| Method of differential display of exposed mRNA by RT/PCR |
| We claim: 1. A method of comparing the presence or level of individual mRNA molecules in two or ... |
|
| Methods of screening for compounds that derepress or increase telomerase activity |
| We claim: 1. Method for screening for a telomerase derepression agent, the method comprising the ... |
|
| Oral vaccines |
| What is claimed is: 1. A protein conjugate comprising an immunogen covalently linked to a carrier ... |
|
|
Cold-active beta-galactosidase, the process for its preparation and the use thereof
| Details |
Inventors: Hoyoux, Anne; Fran.cedilla.ois, Jean-Marie; Dubois, Phillip; Baise, Etienne; Jennes, Isabell; Genicot, Sabine; Gerday, Charles;
Assignee: Universite de Liege (Liege, BE)
Primary Examiner: Hutson; Richard
Assistant Examiner:
Attorney, Agent or Firm: Venable LLP, Kinberg; Robert, Axelrod; Nancy J.
A purified cold-active beta galactosidase enzyme, specific for lactose, having a stable enzymatic activity at a temperature below 8.degree. C. In the presence of lactose, a purified cold-active beta galactosidase enzyme, specific for lactose, having a stable enzymatic activity at a temperature ranging between 0.degree. C. and 50.degree. C. |
|
DETAILED DESCRIPTION The object of the present invention is to hydrolyse lactose by using a .
beta.
-galactosidase, which could overcome the above-mentioned drawbacks which are usually associated to this process, while advantageously avoiding contamination problems during the hydrolysis process and lowering the energy consumption.
This problem is solved according to the present invention by a purified cold-active .
beta.
-galactosidase, specific for lactose, having a stable enzymatic activity at temperatures up to below 8.
degree.
C.
, preferably up to below 6.
degree.
C.
, and specifically at 4.
degree.
C.
, which corresponds to refrigerating conservation temperature for dairy products.
This enzyme of the invention is consequently able to hydrolyse lactose in dairy products and stable enzymatic activity at temperatures up to below 8.
degree.
C.
, preferably up to below 6.
degree.
C.
, and specifically at 4.
degree.
C.
, which corresponds to refrigerating conservation temperature for dairy products.
This enzyme of the invention is consequently able to hydrolyse lactose in dairy products and milk processing at such a low temperature that saprophytes are hindered to proliferate.
The hydrolysis of lactose can be carried out in these refrigeration conditions with no need of a particular treatment to the dairy product concerned.
According to the invention, an enzymatic activity is considered as stable when, in the concerned conditions, the enzyme is capable of lasting long enough to obtain the desired effect, for example, the hydrolysis of a substrate.
According to an embodiment of the invention, the cold-active .
beta.
-galactosidase has a stable enzymatic activity between 0 and 50.
degree.
C.
Advantageously, the cold-active .
beta.
-galactosidase according to the invention has a stable enzymatic activity at a pH range from 6 to 10, preferably from 6 to 8.
Preferably, the cold-active .
beta.
-galactosidase according to the invention has a stable enzymatic activity in presence of calcium and/or galactose, meaning that the activity of this enzyme is neither inhibited by its reaction product nor by products being present in milk
|
| Related patents |
|
|
Method of delivering powder transdermally with needless injector
What we claim is: 1. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian ...
|
|
|
Telomere repeat binding factors and diagnostic and therapeutic use thereof
The present invention provides vertebrate telomeric binding factors (TRFs) that bind to the TTAGGG repeat sequences of telomeres. Such TRFs comprise two key domains: a ...
|
|
|
Protease-activated receptor PAR4 (ZCHEMR2)
What is claimed is: 1. An isolated polynucleotide molecule that encodes a polypeptide comprising amino acid residues 48 to 78 of SEQ ID NO:2. 2. The isolated ...
|
|
|
Systemic drug delivery compositions comprising a polycationi substance
I claim: 1. A method of systemically delivering a pharmaceutically effective amount of a pharmacologically active compound to a mammal comprising: administering to a ...
|
|
|
Nucleic acid-containing composition, its preparation and use
We claim: 1. A composition comprising a deoxyribonucleic acid and a cationic oligopeptide that forms secondary structures, wherein the oligopeptide corresponds to the ...
|
|
|
Peptide-enhanced cationic lipid transfections
OF THE INVENTION The present invention provides improved methods for transfecting eukaryotic cells with nucleic acids by employing peptides or modified peptides in ...
|
|
|
Controlled release formulations coated with aqueous dispersions of acrylic polymers
It is therefore an object of the present invention to provide a controlled release formulation of a substrate comprising an active agent, e.g. a therapeutically active ...
|
|
|
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
What is claimed is: 1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3, C--R.sub.3, halo, NHR.sub.4, ONHR.sub.5 or ON.dbd.R.sub.6, wherein R....
|
|
|
Substituted indazole-O-glucosides
OF THE INVENTION All diabetics, regardless of their genetic and environmental backgrounds, have in common an apparent lack of insulin or inadequate insulin function. B...
|
|
|
Production in Escherichia coli of extracellular Serratia spp. hydrolases
We claim: 1. A method of producing an extracellular hydrolytic Serratia spp. enzyme selected from the group consisting of exocellular nuclease, exocellular phospholipase ...
|
|
|
Gene Therapy 
